Physician profile
Stephen P Warman
NPI 1780642371
$49,625.92
in general payments reported to CMS, 2019-2025
19 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,885 · 2020: $877 · 2021: $923 · 2022: $3,209 · 2023: $6,122 · 2024: $11K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Consulting Fee: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,230.80 |
| Consulting Fee | $18,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $21,164.51 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Aerin Medical INC. | $20,722.64 | 2022-2025 | |
| Stryker Corporation | $3,577.28 | 2019-2025 | Clarifix, Xpress Loprofile, Focess |
| Genzyme Corporation | $1,217.09 | 2021-2025 | |
| Arrinex, INC. | $902.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $662.19 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $388.71 | 2021-2025 | Nucala |
| Optinose US, INC. | $326.37 | 2019-2025 | |
| Allergan, INC. | $197.68 | 2022 | |
| Acclarent, INC | $88.05 | 2019 | |
| Hikma Pharmaceuticals USA | $82.03 | 2023-2024 | Ryaltris |
| Intersect Ent, INC. | $81.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $80.99 | 2022 | |
| Merz North America, INC. | $27.47 | 2019-2020 | |
| Alk-Abello, INC | $26.73 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.32 | 2019 | |
| Merck Sharp & Dohme LLC | $20.31 | 2023 | |
| Abbvie INC. | $19.45 | 2023 | Botox |
| Xoran Technologies LLC | $18.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Warman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.